The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis

Pigment Cell and Melanoma Research

Volumn 27, Issue 5, 2014, Pages 835-838

  Furney, Simon J ^a   Turajlic, Samra ^b   Stamp, Gordon ^c   Thomas, J Meirion ^d   Hayes, Andrew ^d   Strauss, Dirk ^d   Gavrielides, Mike ^a   Xing, Wei ^a   Gore, Martin ^d   Larkin, James ^d   Marais, Richard ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Acral melanoma; Mutational burden; Somatic mutations; Whole genome sequencing

Indexed keywords

COMPARATIVE STUDY; DNA DAMAGE; DNA MUTATIONAL ANALYSIS; GENE DOSAGE; GENETIC VARIATION; GENETICS; HUMAN; HUMAN GENOME; MELANOMA; MUTATION; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN TUMOR;

DNA DAMAGE; DNA MUTATIONAL ANALYSIS; GENE DOSAGE; GENETIC VARIATION; GENOME, HUMAN; HUMANS; MELANOMA; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; SKIN NEOPLASMS;

EID: 84907968949     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12279     Document Type: Article

References (20)

1. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C. et al. (2013). Signatures of mutational processes in human cancer. Nature 500, 415-421.
2. Berger, M.F., Hodis, E., Heffernan, T.P. et al. (2012). Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485, 502-506.
3. Cancer Genome Atlas Research Network (2013). Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059-2074.
4. Ciriello, G., Miller, M.L., Aksoy, B.A., Senbabaoglu, Y., Schultz, N., and Sander, C. (2013). Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 45, 1127-1133.
5. Curtin, J.A., Fridlyand, J., Kageshita, T. et al. (2005). Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 2135-2147.
6. Curtin, J.A., Busam, K., Pinkel, D., and Bastian, B.C. (2006). Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24, 4340-4346.
7. Ellis, M.J., Ding, L., Shen, D. et al. (2012). Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486, 353-360.
8. Forbes, S.A., Tang, G., Bindal, N. et al. (2010). OSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 38 (Database issue), 652-657.
9. Furney, S.J., Turajlic, S., Fenwick, K. et al. (2012). Genomic characterisation of acral melanoma cell lines. Pigment Cell Melanoma Res. 25, 488-492.
10. Furney, S.J., Pedersen, M., Gentien, D. et al. (2013a). SF3B1 Mutations Are Associated with Alternative Splicing in Uveal Melanoma. Cancer Discov. 3, 1122-1129.
11. Furney, S.J., Turajlic, S., Stamp, G. et al. (2013b). Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. J. Pathol. 230, 261-269.
12. Greaves, W.O., Verma, S., Patel, K.P. et al. (2013). Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J. Mol. Diagn. 15, 220-226.
13. Hodis, E., Watson, I.R., Kryukov, G.V. et al. (2012). A landscape of driver mutations in melanoma. Cell 150, 251-263.
14. Krauthammer, M., Kong, Y., Ha, B.H. et al. (2012). Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006-1014.
15. Liau, J.Y., Tsai, J.H., Jeng, Y.M., Chu, C.Y., Kuo, K.T., and Liang, C.W. (2014). TERT Promoter Mutation is Uncommon in Acral Lentiginous Melanoma. J. Cutan. Pathol. 41, 504-508.
16. Pfeifer, G.P., You, Y.H., and Besaratinia, A. (2005). Mutations induced by ultraviolet light. Mutat. Res. 571, 19-31.
17. Phan, A., Touzet, S., Dalle, S., Ronger-Savle, S., Balme, B., and Thomas, L. (2007). Acral lentiginous melanoma: histopathological prognostic features of 121 cases. Br. J. Dermatol. 157, 311-318.
18. Turajlic, S., Furney, S.J., Lambros, M.B. et al. (2012). Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res. 22, 196-207.
19. Turajlic, S., Furney, S.J., Stamp, G. et al. (2014). Whole genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Ann. Oncol. 25, 959-967.
20. Zebary, A., Omholt, K., Vassilaki, I., Hoiom, V., Linden, D., Viberg, L., Kanter-Lewensohn, L., Johansson, C.H., and Hansson, J. (2013). KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma. J. Dermatol. Sci. 72, 284-289.